psychiatryRounds

Connecting Psychiatry - Expert community for all mental health professionals

(PSYCHIATRIC TIMES) - Medical, surgical, and technologic advances have significantly decreased morbidity and improved survival and quality of life in men with cancer. However, sexual dysfunction after oncologic treatment is common and sadly underevaluated and undertreated despite the availability of effective, safe, and simple treatment options. The true prevalence of sexual problems after cancer treatment is unknown due to methodologic problems such as the use of patient self-reports, demographic differences between study and control groups, and unclear definitions.
For example, to define functional erections, investigators have used different cutoff scores of the Sexual Health Inventory for Men (SHIM) or the International Index of Erectile Function (IIEF) with or without phosphodiesterase type J inhibitors, which makes interpretation of the available data very difficult. In addition, physicians tend to only report on erectile dysfunction after cancer treatment, overlooking other sexual dysfunctions such as penile deformities, hypoactive sexual desire disorder, and ejaculatory or orgasmic disorders.

General Sexual Issues
Malignancies and/or cancer treatment can cause a wide variety of sexual health issues. Physical changes (eg, alopecia, weight loss, loss of penile size) and symptoms (eg, fatigue, sleep disorders, nausea, diarrhea) may have a dramatic impact on the patient’s self-esteem and self-image, causing distress, guilt, mood alterations, and an inability to discuss sexual and relationship issues with their partner and physician. Depression or its treatment (selective serotonin-reuptake inhibitors [SSRIs], tricyclic antidepressants [TCAs]) may affect sexual desire as well as erectile, ejaculatory, and orgasmic function. Consequently, psychological support and the use of non-SSRIs/TCAs such as bupropion should always be considered in the management of men with cancer and depression.

Specific Cancers

More specifically, prostate cancer treatment (radiation therapy, radical surgery, androgen ablation) can cause erectile dysfunction (in 14%-98% of patients),[1,2] penile shortening (by 0.5-5 cm in two-thirds of patients),[3] penile deformities (Peyronie’s disease), and ejaculatory/orgasmic problems. In addition, radiation therapy and radical surgery may be associated with severe urinary incontinence, which may interfere with sexual activity. Furthermore, hypogonadism after androgen ablation for adjunctive or palliative prostate cancer management, chemotherapy, opioid use, and stress may further worsen general physical and psychological symptoms, erectile dysfunction, and sexual desire.

Invasive bladder cancer due to its high morbidity, mortality, and impact on body image may be associated with more profound sexual problems. In addition, clinical experience suggests that PDE-5 inhibitors and intracavernosal therapy are not as effective in men who have undergone cystoprostatectomy compared to men who undergo radical prostatectomies.

For full article, please visit:
http://www.psychiatrictimes.com/sexual-issues/article/10165/107748

Views: 6

Comment

You need to be a member of psychiatryRounds to add comments!

Join psychiatryRounds


psychiatryRounds Social Media

Sponsors

CMEinfo: Board Reviews in Anesthesia, Cardiology, Internal Medicine, Radiology

© 2019   Created by PsychiatryRounds Team.   Powered by

Badges  |  Report an Issue  |  Terms of Service